Australian Clinical Labs Limited (ASX:ACL)

Market Cap	541.06M
Revenue (ttm)	741.27M
Net Income (ttm)	32.43M
Shares Out	193.24M
EPS (ttm)	0.17
PE Ratio	16.42
Forward PE	14.87
Dividend	0.13 (4.39%)
Ex-Dividend Date	Sep 1, 2025

Volume	346,618
Average Volume	667,098
Open	2.840
Previous Close	2.800
Day's Range	2.795 - 2.840
52-Week Range	2.380 - 3.830
Beta	1.05
RSI	56.66
Earnings Date	Feb 25, 2026

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,700
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In 2025, Australian Clinical Labs's revenue was 741.27 million, an increase of 6.45% compared to the previous year's 696.37 million. Earnings were 32.43 million, an increase of 35.50%.